diagnosis

2 June, 2025

Blood tests to predict Alzheimer's: a new era of prevention begins

The U.S. Food and Drug Administration (FDA) is moving toward less invasive methods that would allow early detection of early signs of neurological deterioration, opening up new possibilities for prevention and early treatment.
25 March, 2025

First Workshop on Bioanalysis and Clinical Diagnosis, with an Emphasis on Lyme Disease

The first workshop of the EFA2/99 Nanolyme project, funded by the European Interreg Poctefa program, can be followed next Wednesday, April 1nd, at the Río Ebro Campus and on YouTube. To attend, please complete a form.
24 February, 2025

NanoLyme: nanotechnology and artificial intelligence for a new diagnosis of Lyme disease

The IIS Aragón is collaborating with the University of Zaragoza, the CNRS and the Lannemezan University Hospital on this project, which has received funding of over 1 million euros. NanoLyme seeks to directly detect the bacteria responsible for Lyme disease.
13 December, 2024

The Aragonese Primary Care Research Group (GAIAP) of the IIS Aragón, in the EURODATA project

The group will be responsible for the management of Long COVID from Primary Care. To do so, it has launched a survey aimed at family doctors to find out about their experience in the diagnosis and treatment of this condition.
November 13, 2024

ASEICA organizes a “Week of Science in Cancer” with an international congress that will bring together 400 experts

The activities of the “Science Week” in Zaragoza will run from 12 to 16 November 2024. In addition to various informative days and meetings between patients and researchers, several grants will be awarded for cancer research worth a total of 345.000 euros.
September 20, 2024

A new blood test for rapid diagnosis of ALS

A blood test can detect this neurodegenerative disease with 98% accuracy and within 24 hours. The speed of this process will allow treatment to be started earlier, which will translate into better results for patients, say the researchers. It is expected to be available to neurologists within 18 to 24 months.